ZEN
Zenith resumes small-scale oil output in Tunisia after $2.7 million in downtime costs.
Zentek launches ZenGUARD™ direct-to-consumer sales with strong lab data, but no sales figures.
Zenith’s Italian operations saw a 22% profit jump as electricity prices surged.
Zentek faces Nasdaq delisting, moving its shares to OTC Markets in September 2026.
Zentek wins a modest federal supply contract, but revenue impact remains unproven.
Zentek files a patent for a graphite-based EMI coating, but commercialization is distant.
Zenith raised cash, but real business progress and returns remain unproven and distant.
This is a routine IR contract with technical updates, not a catalyst for investors.
Zenith’s biogas deal is all promise, no proof—years from impact, with major execution risks.
This is a routine research coverage deal, not a catalyst for Zentek’s stock.
Zenith’s Reveille stake is a speculative bet, not a proven value driver yet.
Zentek’s first commercial order is progress, but financial impact remains unproven and unclear.
Zenith’s Reveille bet is high-risk, long-term, and lacks near-term financial proof.
Zenith’s solar launch is real, but most promised value is years away and unproven.